Metosartan LN 50 Tablet ER is a combination antihypertensive medication containing Cilnidipine (10mg), Metoprolol Succinate (47.5mg), and Telmisartan (40mg). This extended-release formulation is designed to effectively manage hypertension by targeting multiple physiological pathways. Cilnidipine, a calcium channel blocker, inhibits L-type and N-type calcium channels, leading to vasodilation and reduced peripheral resistance. Metoprolol Succinate, a selective beta-1 adrenergic receptor blocker, decreases heart rate and myocardial contractility, thereby reducing cardiac output and blood pressure. Telmisartan, an angiotensin II receptor blocker (ARB), prevents vasoconstriction and aldosterone secretion by blocking the AT1 receptor, contributing to further blood pressure reduction and renal protection. The synergistic action of these three agents provides comprehensive control of blood pressure, improving cardiovascular outcomes and reducing the risk of stroke, myocardial infarction, and renal impairment. Metosartan LN 50 Tablet ER is indicated for patients with essential hypertension who require combination therapy for optimal blood pressure control. It should be administered under medical supervision, with dosage adjustments based on clinical response and tolerability. Caution is advised in patients with hepatic or renal impairment, and regular monitoring of blood pressure, renal function, and electrolytes is recommended during therapy.